Single-Molecule Real-Time Sequencing (SMRT) Market Report 2026

The single-molecule real-time sequencing (smrt) market size has grown strongly in recent years. It will grow from $3.36 billion in 2025 to $3.63 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to expansion of genomic research initiatives, increasing adoption of next-generation sequencing platforms, growing demand for whole genome sequencing, rising investments in life sciences research, advancements in sequencing chemistry.

The single-molecule real-time sequencing (smrt) market size is expected to see strong growth in the next few years. It will grow to $4.9 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing use of precision medicine approaches, rising demand for population-scale genomics, expansion of clinical genomics applications, growing integration of ai-driven bioinformatics, increasing funding for advanced sequencing technologies. Major trends in the forecast period include increasing adoption of long-read sequencing technologies, rising use of smrt sequencing for structural variant detection, growing demand for high-accuracy epigenetic analysis, expansion of real-time sequencing workflows, enhanced focus on complex genome resolution.

The growing demand for precision medicine is anticipated to drive the expansion of the single-molecule real-time sequencing (SMRT) market in the coming years. Precision medicine, also known as personalized medicine, is a medical strategy that customizes treatment and healthcare approaches for individual patients based on their genetic, environmental, and lifestyle factors. The rising interest in personalized medicine is fueled by advancements in genomic technologies, which allow for more precise and tailored treatments, as well as an increased focus on individualized patient care to achieve better outcomes. Single-molecule real-time sequencing (SMRT) plays a crucial role in precision medicine by delivering detailed and accurate genomic and epigenetic information, supporting improved diagnosis, personalized therapies, and enhanced patient outcomes. For example, in May 2025, the Personalized Medicine Coalition (PMC), a U.S.-based professional organization, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 18 new personalized medicines, representing approximately 38% of all newly approved therapeutic molecular entities. Consequently, the increasing demand for precision medicine is driving the growth of the single-molecule real-time sequencing (SMRT) market.

The increasing prevalence of genetic disorders is expected to drive the growth of the single-molecule real-time sequencing (SMRT) market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual's DNA, which can be inherited or arise from mutations, impacting physical development, metabolism, or overall health. The rising prevalence of genetic disorders is largely attributed to greater awareness, advancements in diagnostic technologies, and factors such as environmental influences and parental age. Single-molecule real-time sequencing (SMRT) is utilized in the study of genetic disorders to provide precise, long-read DNA sequences, enabling the detection of complex mutations and structural variations that conventional methods may overlook. For example, in March 2024, according to Gene People, a UK-based registered charity supporting individuals with genetic disorders, over 6,000 genetic conditions are known, with new ones being identified regularly. In the UK, 1 in 25 children is affected, leading to 30,000 new diagnoses each year and more than 2.4 million people living with genetic conditions. Consequently, the increasing prevalence of genetic disorders is driving growth in the single-molecule real-time sequencing (SMRT) market.

In February 2023, SeqLL, a US-based company providing sequencing instruments and services, including single-molecule real-time (SMRT) sequencing, collaborated with the US Federal Bureau of Investigation to enhance the accuracy and reliability of biological evidence identification in criminal investigations. This collaboration aims to develop sequencing-based forensic technology to improve the analysis of biological evidence in criminal cases. It also seeks to leverage SeqLL's advanced sequencing capabilities to increase the accuracy and efficiency of forensic DNA analysis. The US Federal Bureau of Investigation is a government law-enforcement agency based in the United States.

Major companies operating in the single-molecule real-time sequencing (smrt) market are Thermo Fisher Scientific Inc., Illumina Inc., Qiagen N.V., BGI Group, 10x Genomics Inc., Ginkgo Bioworks Inc., Oxford Nanopore Technologies Limited, Genewiz Inc., Pacific Biosciences of California Inc., Macrogen Inc., Element Biosciences Inc., Asuragen Inc., BioNano Genomics Inc., Zymo Research Corporation, Dovetail Genomics LLC, SeqWell Inc., Paragon Genomics Inc., Nabsys Inc., Eurofins Scientific SE, Novogene Corporation.

North America was the largest region in the single-molecule real-time sequencing (SMRT) market in 2025. The regions covered in the single-molecule real-time sequencing (smrt) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the single-molecule real-time sequencing (smrt) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the single-molecule real-time sequencing market by increasing costs of imported sequencing instruments, optical components, reagents, consumables, and advanced computing hardware required for real-time data processing. North America and Europe are most affected due to reliance on specialized imported sequencing systems, while Asia-Pacific faces cost pressures on instrument manufacturing and consumable sourcing. These tariffs are raising overall system ownership costs and slowing procurement cycles for research institutions. However, they are also encouraging localized manufacturing, regional reagent production, and domestic innovation in sequencing platforms, supporting long-term supply chain resilience.

The single-molecule real-time sequencing (smrt) market research report is one of a series of new reports that provides single-molecule real-time sequencing (smrt) market statistics, including single-molecule real-time sequencing (smrt) industry global market size, regional shares, competitors with a single-molecule real-time sequencing (smrt) market share, detailed single-molecule real-time sequencing (smrt) market segments, market trends and opportunities, and any further data you may need to thrive in the single-molecule real-time sequencing (smrt) industry. This single-molecule real-time sequencing (smrt) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Single-molecule real-time (SMRT) sequencing is a sophisticated DNA sequencing technique that enables the direct observation of DNA synthesis by tracking fluorescently labeled nucleotides in real-time, allowing the generation of long, continuous reads. This method is particularly useful for sequencing complex genomic regions and identifying structural variations.

The primary product categories of single-molecule real-time sequencing (SMRT) include consumables, instruments, and services. SMRT sequencing consumables consist of materials utilized in SMRT sequencing technologies, designed to sequence DNA or RNA molecules in real-time. These consumables are applied in a variety of areas, including DNA sequencing, RNA sequencing, epigenetics, and whole genome sequencing, and are used by a range of end-users such as hospitals, diagnostic laboratories, biopharmaceutical companies, academic institutions, and research centers, among others.

The single-molecule real-time sequencing (SMRT) market consists of revenues earned by entities by service contracts, data analysis, charging for the service and maintenance plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The single-molecule real-time sequencing (SMRT) market also includes sales of sequencing kits, reagents, and specialized chips. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.